查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1967706

基因治疗市场－全球产业规模、份额、趋势、机会和预测：按载体类型、给药方法、适应症、地区和竞争格局划分，2021-2031年

Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vector Type, By Delivery Method, By Indication, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球基因疗法市场预计将从 2025 年的 75.4 亿美元成长到 2031 年的 130.2 亿美元，复合年增长率为 9.53%。

基因疗法是指透过替换、惰性或导入患者细胞内的遗传讯息（基因）来治疗或预防疾病的医疗介入措施。这一市场成长的主要驱动力是罕见遗传疾病和慢性病数量的不断增加，这些疾病迫切需要可持续的治疗方案。此外，病毒载体技术的进步和监管审批流程的简化正在加速核准进程，并促进从临床研究到商业性化产品的转化。

市场概览
预测期 2027-2031
市场规模：2025年 75.4亿美元
市场规模：2031年 130.2亿美元
复合年增长率：2026-2031年 9.53%
成长最快的细分市场 非病毒载体
最大的市场 北美洲

儘管取得了这些进展，但高度复杂的生产流程和相关成本仍然是市场扩充性和普及化的重要障碍。这些经济因素往往导致定价结构超越医疗保险报销体系的承受能力，从而限制了病患获得治疗的机会。根据美国基因与细胞治疗学会（ASGCT）统计，2025年第二季启动的80项新的基因治疗临床试验中，64%集中在肿瘤领域。这项数据表明，儘管面临巨大的经济障碍，该领域仍继续专注于复杂适应症的临床研究。

市场驱动因素

支持性的法规结构和加快核准流程正在从根本上改变市场格局，加速新型治疗方法的商业化进程。监管机构正在简化生物製药的复杂审查流程，例如FDA的「先进再生医学」（RMAT）和「突破性治疗方法」认定，并实施专门的认定方案，以缩短从临床检验到患者用药的时间。这种鼓励创新的环境无疑增加了成功上市的案例数量，并展现了新兴病毒载体和基因编辑技术的有效性。根据Fierce Pharma（2026年1月）报道，FDA在2024年核准了9种新的细胞和基因疗法，创下该领域历史新高。这些监管方面的突破透过提供清晰的商业化路径和促进可持续的行业参与，降低了未来专案的风险。

随着监管政策的推进，生命科学研究领域的投资和资金筹措激增，为高成本的临床开发和生产规模化提供了所需的资金，从而推动了市场扩张。生物製药公司持续资金筹措以推进其研发管线，确保创新候选药物能够在经济波动的影响下顺利通过严格的测试阶段。根据再生医学联盟（Alliance for Regenerative Medicine）2025年1月发布的数据，2024年全球在该领域的投资额达到152亿美元，比上年增长30%。这笔资金流入支持治疗方案多样化且不断扩展的生态系统。美国基因与细胞治疗学会（ASGCT）在2025年11月报告称，全球基因治疗、细胞治疗和RNA治疗的研发管线包含超过3200项正在进行的临床试验。

市场挑战

生产过程的高度复杂性及其相关成本是限制全球基因治疗市场扩充性和商业性潜力的主要障碍。与小分子药物不同，基因治疗依赖复杂的生物过程，例如病毒载体的生产，本身就难以标准化和规模化。这种低的生产效率导致庞大的销售成本，迫使企业设定高价，加重医疗预算负担。因此，支付者通常会设定严格的报销标准，限制患者获得治疗的机会，并减少维持进一步创新所需的收入。

此外，克服这些生产製造的挑战需要大量的资本投入，这为研发公司带来了严峻的财务环境。建造符合良好生产规范 (GMP) 的设施需要大量的前期投资，这会消耗原本可用于拓展产品线的资源。根据再生医学联盟 (Alliance for Regenerative Medicine) 统计，2024 年上半年该领域共筹集了约 109 亿美元的资金。虽然这无疑是一笔巨款，但生物製造和供应链物流的高昂成本意味着大部分资金都用于营运支出，而非临床研发。这正在减缓市场成长和产品商业化的整体步伐。

市场趋势

目前，与合约研发生产机构 (CDMO) 拓展策略合作伙伴关係正有助于解决关键的生产瓶颈。外包给 CDMO 使研发公司能够利用专业的病毒载体生产基础设施，而无需承担自建设施所需的大量资本成本。这项策略降低了技术风险，并透过既定的监管管道加快了临床检验，使创新者能够将资源集中于产品线开发而非程式工程。根据 Matika Biotechnology 于 2025 年 10 月发布的题为「Matika Biotechnology 崛起为领先的 CDMO」的新闻稿，该公司在 2025 年上半年获得了 10 多个新的生产计划，这反映出其正迅速采用外部生产模式来支持其不断扩展的产品线。

同时，从体外给药途径到直接体内给药途径的转变正在改变复杂组织标靶的治疗模式。与仅限于易于获取细胞的体外方法不同，直接体内给药利用精密的载体来治疗中枢神经系统等深部解剖部位。这种方法简化了物流，并将基因疗法的应用范围扩展到以往难以治疗的神经系统疾病。根据国际细胞与基因治疗学会 (ISCT) 于 2025 年 1 月发布的题为《2024 年细胞与基因治疗核准趋势》的报告，Keviridy 的核准是一项突破性成就，它是首个能够直接递送至大脑的基因疗法，证实了这种给药途径的实用性。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球基因治疗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 载体类型（病毒载体、非病毒载体）
    • 给药途径（体内给药、体外给药）
    • 按类型分類的适应症（罕见疾病、癌症、神经系统疾病、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美基因治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲基因治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区基因治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲基因疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲基因治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球基因治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • REGENXBIO Inc.
  • Oxford Biomedica PLC.
  • Voyager Therapeutics Inc.
  • Human Stem Cells Institute
  • Dimension Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • bluebird bio, Inc.
  • Novartis AG
  • uniQure NV.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 17109

The Global Gene Therapy Market is projected to expand from USD 7.54 Billion in 2025 to USD 13.02 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 9.53%. Gene therapy is characterized as a medical intervention that alters the genetic instructions within a patient's cells-by replacing, inactivating, or introducing genes-to treat or prevent diseases. This market growth is primarily fueled by the increasing prevalence of rare genetic disorders and chronic conditions, which generate an urgent need for long-lasting therapeutic solutions. Additionally, advancements in viral vector technologies and streamlined regulatory designations are accelerating the approval process, facilitating the transition of clinical research into commercially viable products.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.54 Billion
Market Size 2031USD 13.02 Billion
CAGR 2026-20319.53%
Fastest Growing SegmentNon-viral vectors
Largest MarketNorth America

Despite this progress, the high complexity of manufacturing and its associated costs present a significant barrier to market scalability and accessibility. These economic factors often lead to pricing structures that burden healthcare reimbursement systems and restrict patient adoption. According to the American Society of Gene & Cell Therapy, oncology indications comprised 64% of the 80 newly initiated gene therapy clinical trials in the second quarter of 2025. This statistic underscores the sector's continued clinical focus on complex indications, even in the face of substantial financial hurdles.

Market Driver

Supportive regulatory frameworks and expedited approval pathways are fundamentally transforming the market by accelerating the commercialization of novel treatments. Regulatory agencies have implemented specialized designations, such as the FDA's Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy status, which streamline the review process for complex biologic products and shorten the timeline between clinical validation and patient access. This pro-innovation environment has driven a tangible increase in successful market entries, effectively validating emerging viral vector and gene-editing technologies. According to Fierce Pharma in January 2026, the FDA approved nine new cell and gene therapies in 2024, setting a record for the sector; these regulatory milestones reduce risks for future programs and encourage sustained industrial participation by demonstrating a clear path to commercialization.

Concurrent with regulatory advancements, a surge in investment and funding for life sciences research is propelling market expansion by providing the essential capital needed for high-cost clinical development and manufacturing scale-up. Biopharmaceutical developers continue to secure significant financial backing to advance their pipelines, ensuring that innovative candidates can progress through rigorous testing phases despite broader economic fluctuations. According to the Alliance for Regenerative Medicine in January 2025, the sector attracted $15.2 billion in global investment in 2024, representing a 30% year-over-year increase. This influx of capital supports a diverse and expanding ecosystem of therapeutic options, with the American Society of Gene & Cell Therapy reporting in November 2025 that the global pipeline included more than 3,200 active clinical trials for gene, cell, and RNA therapies.

Market Challenge

The high complexity of manufacturing and the associated costs constitute a formidable barrier that directly impedes the scalability and commercial potential of the Global Gene Therapy Market. Unlike small-molecule drugs, gene therapies depend on intricate biological processes, such as viral vector production, which are inherently difficult to standardize and scale. This lack of manufacturing efficiency results in exorbitant Cost of Goods Sold (COGS), forcing companies to set high list prices that strain healthcare budgets. Consequently, payers often impose strict reimbursement criteria, which limits patient access and reduces the revenue potential necessary to sustain further innovation.

Furthermore, the capital-intensive nature of overcoming these manufacturing hurdles creates a challenging financial environment for developers. Establishing facilities that comply with Good Manufacturing Practice (GMP) requires massive upfront capital, draining resources that could otherwise fund pipeline expansion. According to the Alliance for Regenerative Medicine, the sector raised approximately $10.9 billion in investment during the first half of 2024. While this funding is substantial, the extreme costs associated with biomanufacturing and supply chain logistics mean that a significant portion of this capital is absorbed by operational expenses rather than clinical advancement, thereby slowing the overall rate of market growth and product commercialization.

Market Trends

The proliferation of strategic partnerships with Contract Development and Manufacturing Organizations (CDMOs) is currently addressing critical manufacturing bottlenecks. By outsourcing to CDMOs, developers gain access to specialized viral vector infrastructure without the prohibitive capital costs of building internal facilities. This strategy mitigates technical risks and expedites clinical validation through established regulatory pathways, allowing innovators to focus resources on pipeline development rather than process engineering. According to a press release from Matica Biotechnology in October 2025 titled 'Matica Biotechnology Emerges as the Go-To CDMO,' the company secured over 10 new manufacturing projects in the first half of 2025, reflecting the sector's rapid adoption of externalized production to support expanding pipelines.

Simultaneously, the shift from ex vivo to direct in vivo administration routes is transforming the therapeutic landscape for complex tissue targets. Unlike ex vivo methods, which are limited to accessible cells, direct in vivo delivery utilizes advanced vectors to treat deep anatomical sites such as the central nervous system. This approach simplifies logistics and extends the reach of gene therapy to previously untreatable neurological conditions. According to the International Society for Cell & Gene Therapy's January 2025 article 'Cell & Gene Therapy Approvals in 2024,' the approval of Kebilidi marked a milestone as the first gene therapy directly administered to the brain, confirming the viability of this administration route.

Key Market Players

  • REGENXBIO Inc.
  • Oxford Biomedica PLC.
  • Voyager Therapeutics Inc.
  • Human Stem Cells Institute
  • Dimension Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • bluebird bio, Inc.
  • Novartis AG
  • uniQure NV.

Report Scope

In this report, the Global Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Therapy Market, By Vector Type

  • Viral Vector
  • Non-Viral Vector

Gene Therapy Market, By Delivery Method

  • In-Vivo
  • Ex-Vivo

Gene Therapy Market, By Indication

  • Rare Diseases
  • Cancer
  • Neurological Diseases
  • Others

Gene Therapy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Therapy Market.

Available Customizations:

Global Gene Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
    • 5.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 5.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Gene Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Vector Type
    • 6.2.2. By Delivery Method
    • 6.2.3. By Indication
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gene Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Vector Type
        • 6.3.1.2.2. By Delivery Method
        • 6.3.1.2.3. By Indication
    • 6.3.2. Canada Gene Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Vector Type
        • 6.3.2.2.2. By Delivery Method
        • 6.3.2.2.3. By Indication
    • 6.3.3. Mexico Gene Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Vector Type
        • 6.3.3.2.2. By Delivery Method
        • 6.3.3.2.3. By Indication

7. Europe Gene Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Vector Type
    • 7.2.2. By Delivery Method
    • 7.2.3. By Indication
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gene Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Vector Type
        • 7.3.1.2.2. By Delivery Method
        • 7.3.1.2.3. By Indication
    • 7.3.2. France Gene Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Vector Type
        • 7.3.2.2.2. By Delivery Method
        • 7.3.2.2.3. By Indication
    • 7.3.3. United Kingdom Gene Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Vector Type
        • 7.3.3.2.2. By Delivery Method
        • 7.3.3.2.3. By Indication
    • 7.3.4. Italy Gene Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Vector Type
        • 7.3.4.2.2. By Delivery Method
        • 7.3.4.2.3. By Indication
    • 7.3.5. Spain Gene Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Vector Type
        • 7.3.5.2.2. By Delivery Method
        • 7.3.5.2.3. By Indication

8. Asia Pacific Gene Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Vector Type
    • 8.2.2. By Delivery Method
    • 8.2.3. By Indication
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Gene Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Vector Type
        • 8.3.1.2.2. By Delivery Method
        • 8.3.1.2.3. By Indication
    • 8.3.2. India Gene Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Vector Type
        • 8.3.2.2.2. By Delivery Method
        • 8.3.2.2.3. By Indication
    • 8.3.3. Japan Gene Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Vector Type
        • 8.3.3.2.2. By Delivery Method
        • 8.3.3.2.3. By Indication
    • 8.3.4. South Korea Gene Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Vector Type
        • 8.3.4.2.2. By Delivery Method
        • 8.3.4.2.3. By Indication
    • 8.3.5. Australia Gene Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Vector Type
        • 8.3.5.2.2. By Delivery Method
        • 8.3.5.2.3. By Indication

9. Middle East & Africa Gene Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Vector Type
    • 9.2.2. By Delivery Method
    • 9.2.3. By Indication
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Gene Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Vector Type
        • 9.3.1.2.2. By Delivery Method
        • 9.3.1.2.3. By Indication
    • 9.3.2. UAE Gene Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Vector Type
        • 9.3.2.2.2. By Delivery Method
        • 9.3.2.2.3. By Indication
    • 9.3.3. South Africa Gene Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Vector Type
        • 9.3.3.2.2. By Delivery Method
        • 9.3.3.2.3. By Indication

10. South America Gene Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Vector Type
    • 10.2.2. By Delivery Method
    • 10.2.3. By Indication
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gene Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Vector Type
        • 10.3.1.2.2. By Delivery Method
        • 10.3.1.2.3. By Indication
    • 10.3.2. Colombia Gene Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Vector Type
        • 10.3.2.2.2. By Delivery Method
        • 10.3.2.2.3. By Indication
    • 10.3.3. Argentina Gene Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Vector Type
        • 10.3.3.2.2. By Delivery Method
        • 10.3.3.2.3. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Gene Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. REGENXBIO Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Oxford Biomedica PLC.
  • 15.3. Voyager Therapeutics Inc.
  • 15.4. Human Stem Cells Institute
  • 15.5. Dimension Therapeutics, Inc.
  • 15.6. Bristol-Myers Squibb Company
  • 15.7. Sanofi
  • 15.8. F. Hoffmann-La Roche Ltd
  • 15.9. bluebird bio, Inc.
  • 15.10. Novartis AG
  • 15.11. uniQure NV.

16. Strategic Recommendations

17. About Us & Disclaimer